<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39401037</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>14</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2574-3805</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA network open</Title><ISOAbbreviation>JAMA Netw Open</ISOAbbreviation></Journal><ArticleTitle>Recovery From COVID-19-Related Disruptions in Cancer Detection.</ArticleTitle><Pagination><StartPage>e2439263</StartPage><MedlinePgn>e2439263</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e2439263</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamanetworkopen.2024.39263</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="UNASSIGNED">The COVID-19 pandemic impacted the timely diagnosis of cancer, which persisted as the second leading cause of death in the US throughout the pandemic.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">To evaluate the disruption and potential recovery in cancer detection during the first (2020) and second (2021) years of the COVID-19 pandemic.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="UNASSIGNED">This cross-sectional study involved an epidemiologic analysis of nationally representative, population-based cancer incidence data from the Surveillance, Epidemiology, and End Results (SEER) Program. Included patients were diagnosed with incident cancer from January 1, 2000, through December 31, 2021. The analysis was conducted in May 2024 using the April 2024 SEER data release, which includes incidence data through December 31, 2021.</AbstractText><AbstractText Label="EXPOSURES" NlmCategory="UNASSIGNED">Diagnosis of cancer during the first 2 years of the COVID-19 pandemic (2020, 2021).</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="UNASSIGNED">Difference between the expected and observed cancer incidence in 2020 compared with 2021, with additional analyses by demographic subgroups (sex, race and ethnicity, and age group) and community (county-level) characteristics.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">The analysis included 15 831 912 patients diagnosed with invasive cancer between 2000 and 2021, including 759 810 patients in 2020 and 825 645 in 2021. The median age was 65 years (IQR, 56-75 years), and 51.0% were male. The percentage difference between the expected and observed cancer incidence was -8.6% (95% CI, -9.1% to -8.1%) in 2020, with no significant difference in 2021 (-0.2%; 95% CI, -0.7% to 0.4%). These translated to a cumulative (2020-2021) deficit in observed vs expected cases of -127 931 (95% CI, -139 206 to -116 655). Subgroup analyses revealed that incidence rates remained substantially depressed from expected rates into 2021 for patients living in the most rural counties (-4.9%; 95% CI, -6.7% to -3.1%). The cancer sites with the largest cumulative deficit in observed vs expected cases included lung and bronchus (-24 940 cases; 95% CI, -28 936 to -20 944 cases), prostate (-14 104 cases; 95% CI, -27 472 to -736 cases), and melanoma (-10 274 cases; 95% CI, -12 825 to -7724 cases).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="UNASSIGNED">This cross-sectional study of nationally representative registry data found that cancer incidence recovered meaningfully in 2021 following substantial disruptions in 2020. However, incidence rates need to recover further to address the substantial number of patients with undiagnosed cancer during the pandemic.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Uriel</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Cedars-Sinai Medical Center, Los Angeles, California.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Case Comprehensive Cancer Center, School of Medicine, Case Western Reserve University, Cleveland, Ohio.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Population and Quantitative Health Sciences, School of Medicine, Case Western Reserve University, Cleveland, Ohio.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Community Health Integration, School of Medicine, Case Western Reserve University, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rose</LastName><ForeName>Johnie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Case Comprehensive Cancer Center, School of Medicine, Case Western Reserve University, Cleveland, Ohio.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Population and Quantitative Health Sciences, School of Medicine, Case Western Reserve University, Cleveland, Ohio.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Community Health Integration, School of Medicine, Case Western Reserve University, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carroll</LastName><ForeName>Bryan T</ForeName><Initials>BT</Initials><AffiliationInfo><Affiliation>Case Comprehensive Cancer Center, School of Medicine, Case Western Reserve University, Cleveland, Ohio.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Dermatology, University Hospitals Cleveland Medical Center, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoehn</LastName><ForeName>Richard S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Case Comprehensive Cancer Center, School of Medicine, Case Western Reserve University, Cleveland, Ohio.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Surgical Oncology, University Hospitals Cleveland Medical Center, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Case Comprehensive Cancer Center, School of Medicine, Case Western Reserve University, Cleveland, Ohio.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiation Oncology, School of Medicine, University of California, Irvine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bordeaux</LastName><ForeName>Jeremy S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Case Comprehensive Cancer Center, School of Medicine, Case Western Reserve University, Cleveland, Ohio.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Dermatology, University Hospitals Cleveland Medical Center, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koroukian</LastName><ForeName>Siran M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Case Comprehensive Cancer Center, School of Medicine, Case Western Reserve University, Cleveland, Ohio.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Population and Quantitative Health Sciences, School of Medicine, Case Western Reserve University, Cleveland, Ohio.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Community Health Integration, School of Medicine, Case Western Reserve University, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Netw Open</MedlineTA><NlmUniqueID>101729235</NlmUniqueID><ISSNLinking>2574-3805</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018426" MajorTopicYN="Y">SEER Program</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055088" MajorTopicYN="N">Early Detection of Cancer</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Koroukian reported receiving grants from the National Institutes of Health, Centers for Disease Control and Prevention, American Cancer Society, and Cleveland Clinic Foundation, including a subcontract from Celgene Corporation, and receiving travel reimbursement from the American Association for Cancer Research outside the submitted work. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>22</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>12</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>11</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39401037</ArticleId><ArticleId IdType="pmc">PMC11474412</ArticleId><ArticleId IdType="doi">10.1001/jamanetworkopen.2024.39263</ArticleId><ArticleId IdType="pii">2824734</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fedewa SA, Star J, Bandi P, et al. . Changes in cancer screening in the US during the COVID-19 pandemic. JAMA Netw Open. 2022;5(6):e2215490. doi:10.1001/jamanetworkopen.2022.15490</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.15490</ArticleId><ArticleId IdType="pmc">PMC9166223</ArticleId><ArticleId IdType="pubmed">35657622</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Elsaid MI, DeGraffinreid C, Champion VL, Paskett ED; Impact of COVID-19 on Behaviors across the Cancer Control Continuum in Ohio group . Impact of the COVID-19 pandemic on cancer screening delays. J Clin Oncol. 2023;41(17):3194-3202. doi:10.1200/JCO.22.01704</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.22.01704</ArticleId><ArticleId IdType="pmc">PMC10256430</ArticleId><ArticleId IdType="pubmed">36735899</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim U, Koroukian S, Rose J, Hoehn RS, Carroll BT. US cancer detection decreased nearly 9 percent during the first year of the COVID-19 pandemic. Health Aff (Millwood). 2024;43(1):125-130. doi:10.1377/hlthaff.2023.00767</Citation><ArticleIdList><ArticleId IdType="doi">10.1377/hlthaff.2023.00767</ArticleId><ArticleId IdType="pubmed">38190599</ArticleId></ArticleIdList></Reference><Reference><Citation>Burus T, Lei F, Huang B, et al. . Undiagnosed cancer cases in the US during the first 10 months of the COVID-19 pandemic. JAMA Oncol. 2024;10(4):500-507. doi:10.1001/jamaoncol.2023.6969</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoncol.2023.6969</ArticleId><ArticleId IdType="pmc">PMC10884945</ArticleId><ArticleId IdType="pubmed">38386344</ArticleId></ArticleIdList></Reference><Reference><Citation>Nogueira LM, Schafer EJ, Fan Q, et al. . Assessment of changes in cancer treatment during the first year of the COVID-19 pandemic in the US. JAMA Oncol. 2024;10(1):109-114. doi:10.1001/jamaoncol.2023.4513</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoncol.2023.4513</ArticleId><ArticleId IdType="pmc">PMC10636648</ArticleId><ArticleId IdType="pubmed">37943539</ArticleId></ArticleIdList></Reference><Reference><Citation>Chavez-MacGregor M, Lei X, Zhao H, Scheet P, Giordano SH. Evaluation of COVID-19 mortality and adverse outcomes in US patients with or without cancer. JAMA Oncol. 2022;8(1):69-78. doi:10.1001/jamaoncol.2021.5148</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoncol.2021.5148</ArticleId><ArticleId IdType="pmc">PMC8554684</ArticleId><ArticleId IdType="pubmed">34709356</ArticleId></ArticleIdList></Reference><Reference><Citation>Ofer J, Drozdinsky G, Basharim B, Turjeman A, Eliakim-Raz N, Stemmer SM. Mortality and hospitalization risks in patients with cancer and the SARS-CoV-2 Omicron variant. JAMA Oncol. 2024;10(1):137-138. doi:10.1001/jamaoncol.2023.5042</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoncol.2023.5042</ArticleId><ArticleId IdType="pmc">PMC10666037</ArticleId><ArticleId IdType="pubmed">37991749</ArticleId></ArticleIdList></Reference><Reference><Citation>Howlader N, Bhattacharya M, Scoppa S, et al. . Cancer and COVID-19: US cancer incidence rates during the first year of the pandemic. J Natl Cancer Inst. 2024;116(2):208-215. doi:10.1093/jnci/djad205</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnci/djad205</ArticleId><ArticleId IdType="pmc">PMC10852612</ArticleId><ArticleId IdType="pubmed">37796818</ArticleId></ArticleIdList></Reference><Reference><Citation>Mannelli C. Whose life to save? scarce resources allocation in the COVID-19 outbreak. J Med Ethics. 2020;46(6):364-366. doi:10.1136/medethics-2020-106227</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/medethics-2020-106227</ArticleId><ArticleId IdType="pubmed">32277018</ArticleId></ArticleIdList></Reference><Reference><Citation>Papageorge NW, Zahn MV, Belot M, et al. . Socio-demographic factors associated with self-protecting behavior during the COVID-19 pandemic. J Popul Econ. 2021;34(2):691-738. doi:10.1007/s00148-020-00818-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00148-020-00818-x</ArticleId><ArticleId IdType="pmc">PMC7807230</ArticleId><ArticleId IdType="pubmed">33462529</ArticleId></ArticleIdList></Reference><Reference><Citation>Kichloo A, Albosta M, Dettloff K, et al. . Telemedicine, the current COVID-19 pandemic and the future: a narrative review and perspectives moving forward in the USA. Fam Med Community Health. 2020;8(3):e000530. doi:10.1136/fmch-2020-000530</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/fmch-2020-000530</ArticleId><ArticleId IdType="pmc">PMC7437610</ArticleId><ArticleId IdType="pubmed">32816942</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoff BK, Blalock TW, Swerlick RA, MacKelfresh JB, Lawley LP, Chen SC. Guiding principles for prioritization of limited in-person dermatology appointments during the COVID-19 pandemic. J Am Acad Dermatol. 2020;83(4):1228-1230. doi:10.1016/j.jaad.2020.07.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaad.2020.07.024</ArticleId><ArticleId IdType="pmc">PMC7363593</ArticleId><ArticleId IdType="pubmed">32682028</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabatabai T, Thompson H, Cheung K, et al. . Assessment of effectiveness of COVID-19 pandemic scheduling triage in an academic dermatology clinic. J Am Acad Dermatol. 2024;90(6):1296-1299. doi:10.1016/j.jaad.2024.01.081</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaad.2024.01.081</ArticleId><ArticleId IdType="pubmed">38395227</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaves ALF, Castro AF, Marta GN, et al. . Emergency changes in international guidelines on treatment for head and neck cancer patients during the COVID-19 pandemic. Oral Oncol. 2020;107:104734. doi:10.1016/j.oraloncology.2020.104734</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.oraloncology.2020.104734</ArticleId><ArticleId IdType="pmc">PMC7180373</ArticleId><ArticleId IdType="pubmed">32353793</ArticleId></ArticleIdList></Reference><Reference><Citation>Waisberg F, Enrico D, Angel M, Chacón M. Cancer treatment adaptations in the COVID-19 era. JCO Oncol Pract. 2020;16(6):305-307. doi:10.1200/OP.20.00218</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/OP.20.00218</ArticleId><ArticleId IdType="pmc">PMC7292479</ArticleId><ArticleId IdType="pubmed">32324487</ArticleId></ArticleIdList></Reference><Reference><Citation>Segelov E, Underhill C, Prenen H, et al. . Practical considerations for treating patients with cancer in the COVID-19 pandemic. JCO Oncol Pract. 2020;16(8):467-482. doi:10.1200/OP.20.00229</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/OP.20.00229</ArticleId><ArticleId IdType="pubmed">32401686</ArticleId></ArticleIdList></Reference><Reference><Citation>Joinpoint Regression Program. Version 4.9.1.0. National Cancer Institute; April 2022.</Citation></Reference><Reference><Citation>Huang L, Midthune D, Krapcho M, Zou Z, Horner MJ, Feuer EJ. Adjusting for reporting delay in cancer incidence when combining different sets of cancer registries. Biom J. 2013;55(5):755-770. doi:10.1002/bimj.201100191</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bimj.201100191</ArticleId><ArticleId IdType="pubmed">23873707</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold JAW. Race, ethnicity, and age trends in persons who died from COVID-19—United States, May-August 2020. MMWR Morb Mortal Wkly Rep. 2020;69(42):1517-1521. doi:10.15585/mmwr.mm6942e1</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6942e1</ArticleId><ArticleId IdType="pmc">PMC7583501</ArticleId><ArticleId IdType="pubmed">33090984</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward E, Jemal A, Cokkinides V, et al. . Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin. 2004;54(2):78-93. doi:10.3322/canjclin.54.2.78</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/canjclin.54.2.78</ArticleId><ArticleId IdType="pubmed">15061598</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiwari RC, Clegg LX, Zou Z. Efficient interval estimation for age-adjusted cancer rates. Stat Methods Med Res. 2006;15(6):547-569. doi:10.1177/0962280206070621</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0962280206070621</ArticleId><ArticleId IdType="pubmed">17260923</ArticleId></ArticleIdList></Reference><Reference><Citation>Clegg LX, Reichman ME, Miller BA, et al. . Impact of socioeconomic status on cancer incidence and stage at diagnosis: selected findings from the surveillance, epidemiology, and end results: National Longitudinal Mortality Study. Cancer Causes Control. 2009;20(4):417-435. doi:10.1007/s10552-008-9256-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10552-008-9256-0</ArticleId><ArticleId IdType="pmc">PMC2711979</ArticleId><ArticleId IdType="pubmed">19002764</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;19(3):335-351. doi:10.1002/(SICI)1097-0258(20000215)19:3&lt;335::AID-SIM336&gt;3.0.CO;2-Z</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-0258(20000215)19:3&lt;335::AID-SIM336&gt;3.0.CO;2-Z</ArticleId><ArticleId IdType="pubmed">10649300</ArticleId></ArticleIdList></Reference><Reference><Citation>Star J, Bandi P, Siegel RL, et al. . Cancer screening in the United States during the second year of the COVID-19 pandemic. J Clin Oncol. 2023;41(27):4352-4359. doi:10.1200/JCO.22.02170</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.22.02170</ArticleId><ArticleId IdType="pmc">PMC10911528</ArticleId><ArticleId IdType="pubmed">36821800</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee W, Kim H, Choi HM, et al. . Urban environments and COVID-19 in three Eastern states of the United States. Sci Total Environ. 2021;779:146334. doi:10.1016/j.scitotenv.2021.146334</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.scitotenv.2021.146334</ArticleId><ArticleId IdType="pmc">PMC7952127</ArticleId><ArticleId IdType="pubmed">33744577</ArticleId></ArticleIdList></Reference><Reference><Citation>Yabroff KR, Han X, Zhao J, Nogueira L, Jemal A. Rural cancer disparities in the United States: a multilevel framework to improve access to care and patient outcomes. JCO Oncol Pract. 2020;16(7):409-413. doi:10.1200/OP.20.00352</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/OP.20.00352</ArticleId><ArticleId IdType="pubmed">32574130</ArticleId></ArticleIdList></Reference><Reference><Citation>National Cancer Institute. Surveillance, Epidemiology, and End Results Program . Accessed April 7, 2024. https://seer.cancer.gov/</Citation></Reference><Reference><Citation>Cancer Statistics Center . Explore cancer statistics. American Cancer Society. Accessed September 3, 2024. https://cancerstatisticscenter.cancer.org/#/</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention . About US cancer statistics. Updated June 13, 2024. Accessed September 3, 2024. https://www.cdc.gov/united-states-cancer-statistics/about/index.html</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>